Cassava Sciences Inc (SAVA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cassava Sciences Inc stock (SAVA) is currently trading at $1.83. Cassava Sciences Inc PS ratio (Price-to-Sales) is 2.54. Analyst consensus price target for SAVA is $8.00. WallStSmart rates SAVA as Sell.
- SAVA PE ratio analysis and historical PE chart
- SAVA PS ratio (Price-to-Sales) history and trend
- SAVA intrinsic value — DCF, Graham Number, EPV models
- SAVA stock price prediction 2025 2026 2027 2028 2029 2030
- SAVA fair value vs current price
- SAVA insider transactions and insider buying
- Is SAVA undervalued or overvalued?
- Cassava Sciences Inc financial analysis — revenue, earnings, cash flow
- SAVA Piotroski F-Score and Altman Z-Score
- SAVA analyst price target and Smart Rating
Cassava Sciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Cassava Sciences Inc (SAVA) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Cassava Sciences Inc (SAVA) Key Strengths (1)
Trading at 1.18x book value, attractively priced
Supporting Valuation Data
Cassava Sciences Inc (SAVA) Areas to Watch (5)
Company is destroying shareholder value
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Growth is fairly priced, not cheap, not expensive
Revenue is fairly priced at 2.54x sales
Supporting Valuation Data
Cassava Sciences Inc (SAVA) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 8.0/10) while 5 fall into concern territory (avg 3.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.18) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Market Cap, Institutional Own.. Some valuation metrics including PEG Ratio (1.62), Price/Sales (2.54) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -88.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -88.90% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SAVA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SAVA's Price-to-Sales ratio of 2.54x sits near its historical average of 2.54x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 2.54x set in Mar 2026, and 0% above its historical low of 2.54x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Cassava Sciences Inc (SAVA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Cassava Sciences Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -10M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Cassava Sciences Inc.
Bottom Line
Cassava Sciences Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Cassava Sciences Inc(SAVA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Cassava Sciences, Inc., a clinical-stage biotechnology company, develops drugs for neurodegenerative diseases. The company is headquartered in Austin, Texas.